

Natalie S Grover

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3039908/publications.pdf>

Version: 2024-02-01

28
papers

724
citations

623734

14
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

730
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
2	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
3	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
4	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 1255-1263.	5.2	26
5	The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 197.	2.5	4
6	Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 86-94.	1.3	4
7	Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 68-75.	1.3	4
8	Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 ⁺ Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 499-513.	1.6	5
9	Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. <i>Blood</i> , 2021, 137, 3306-3309.	1.4	26
10	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
11	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	5.2	11
12	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
13	CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma. <i>Blood</i> , 2021, 138, 742-742.	1.4	16
14	Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 5925-5928.	5.2	19
15	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3794-3804.	1.6	235
16	A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 1508-1511.	1.3	4
17	Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2880-2889.	1.3	13
18	Challenges of driving CD30-directed CAR-T cells to the clinic. <i>BMC Cancer</i> , 2019, 19, 203.	2.6	41

#	ARTICLE	IF	CITATIONS
19	Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 3233-3233.	1.4	6
20	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	4.1	40
21	Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T lymphoma: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2018, 59, 2121-2127.	1.3	29
22	Hodgkin Lymphoma With Multiple Autoimmune Disorders: Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e365-e368.	0.4	2
23	Targeting Immune System Alterations in Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 358-369.	2.3	5
24	A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 281-289.	2.5	50
25	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	1.4	3
26	Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. <i>Pharmaceuticals</i> , 2015, 8, 607-636.	3.8	15
27	Significant Unmet Need in Fertility Counseling and Sperm Cryopreservation in Young Males with Cancer: A Single-Center Analysis. <i>Blood</i> , 2015, 126, 4488-4488.	1.4	0
28	A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. <i>EJHaem</i> , 0, , .	1.0	3